Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk.

about

Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk.

Item

http://www.wikidata.org/entity/Q55259913

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Combination Treatment of SGLT2 ...... tabolism and Cardiorenal Risk.

@en

Combination Treatment of SGLT2 ...... tabolism and Cardiorenal Risk.

@nl

type

Item

label

Combination Treatment of SGLT2 ...... tabolism and Cardiorenal Risk.

@en

Combination Treatment of SGLT2 ...... tabolism and Cardiorenal Risk.

@nl

prefLabel

Combination Treatment of SGLT2 ...... tabolism and Cardiorenal Risk.

@en

Combination Treatment of SGLT2 ...... tabolism and Cardiorenal Risk.

@nl

P1476

Combination Treatment of SGLT2 ...... etabolism and Cardiorenal Risk

@en

P2093

David S H Bell

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacological aspects of the safety of gliflozins.

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity.

Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice.

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Severe Hypoglycemia Requiring Medical Intervention in a Large Cohort of Adults With Diabetes Receiving Care in U.S. Integrated Health Care Delivery Systems: 2005-2011.

The role of fat topology in the risk of disease.

Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.

P2888

s13300-018-0420-6

P304

919-926

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13300-018-0420-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Edison Goncalves

P577

2018-04-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1103182896

http://www.w3.org/2001/XMLSchema#string

P698

29623594

http://www.w3.org/2001/XMLSchema#string

P932

5984923

http://www.w3.org/2001/XMLSchema#string